Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase

NCT02776735 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02776735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02776735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
September 6, 2016
Completion date
December 27, 2023
Enrollment
102 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis